Verona Pharma Announces March 2025 Investor Conference Participation

Company Overview - Verona Pharma plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases with significant unmet medical needs [3] - The company's first commercial product, Ohtuvayre™ (ensifentrine), is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule [3] - Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma, and other respiratory diseases [3] Upcoming Conferences - Verona Pharma's senior management will present a company overview at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 11:10 a.m. ET in Boston, MA [1] - The company will also present at the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 8:40 a.m. ET in Miami, FL [1] - A webcast of each conference presentation will be available on the company's website [1]